Pfizer reported a decline in fourth-quarter sales Tuesday, pointing to headwinds of a stronger dollar and competition from generic drugs as more patents expire, issues it says aren't likely to abate this year. Revenue fell 3% to $13.1 billion, but beat Wall Street consensus estimates of $12.9 billion. Profit was $1.2 billion, [...]